Welcome to our dedicated page for TELESIS BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TELESIS BIO stock.
Telesis Bio, Inc. (NASDAQ: TBIO) is a leading synthetic biology company revolutionizing the field with its advanced technology for building high-quality synthetic DNA and mRNA. Based in San Diego, Telesis Bio manufactures and distributes a variety of laboratory equipment including synthetic biology instruments, reagents, and related services that empower researchers in various scientific domains.
The company's flagship product, the BioXp® system, is an award-winning, fully automated genomics workstation that streamlines the entire synthesis, cloning, and amplification workflow. This system consolidates various processes, enabling the creation of double-stranded DNA fragments, automated cloning, and next-generation sequencing DNA library preparation. The BioXp system is complemented by BioXp kits, Benchtop reagents, and BioXp biofoundry services, all designed to accelerate synthetic biology workflows.
Telesis Bio is known for its industry-standard Gibson Assembly® method, an essential tool for assembling DNA molecules. The company recently launched the groundbreaking Gibson SOLA platform, which supports high-throughput drug discovery applications and promises significant advantages over existing solutions. This platform ensures high-fidelity synthesis of synthetic oligonucleotides, genes, and transfection-ready mRNA, allowing researchers to achieve results within unprecedented timelines.
In its recent updates, Telesis Bio announced several milestones, including the introduction of new kits to expand their suite of NGS Library Prep solutions on the BioXp System. The company has shown resilience and adaptability, with revenue for the third quarter of 2023 at $5.6 million, despite a challenging economic environment. Their ongoing efforts in cost-cutting have effectively reduced operating expenses and net losses, laying a strong foundation for future growth.
Telesis Bio's technology is crucial in multiple fields, including precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Researchers worldwide rely on their solutions to accelerate the design-build-test paradigm, pushing the boundaries of synthetic biology to address some of humanity's greatest challenges.
As Telesis Bio continues to innovate and expand, they remain committed to providing researchers with the tools and resources needed to drive scientific discovery and application. For more information, visit www.telesisbio.com.
Telesis Bio Inc. (NASDAQ: TBIO) announced the expansion of its BioXp® Select Kit product line with two new kits for DNA amplification and scale-up. These kits enable automated and on-demand synthesis of transfection-scale DNA from customers' own DNA fragments or plasmid DNA. This innovation is expected to significantly reduce the time and steps required for DNA cloning and scaling, enhancing research workflows. Telesis Bio plans to release additional BioXp® kits throughout 2023, which will further improve processes like NGS Library Preparation and CRISPR gRNA synthesis.
Telesis Bio Inc. (NASDAQ: TBIO) reported a record revenue of $9.5 million for 4QFY22, reflecting a remarkable 208% increase compared to 4QFY21. The company's BioXp revenue rose 158% to $3.4 million. Gross margin improved to 68%, up from 29% year-over-year, despite operating expenses increasing to $14.3 million. The net loss narrowed to $8.1 million from $12.5 million the previous year. For 2023, Telesis Bio expects total revenue exceeding $45 million and gross margin between 55% and 59%. The company is focused on strategic investments to drive long-term growth and profitability.
Telesis Bio Inc. (NASDAQ: TBIO) announced that Daniel Gibson, Ph.D., CTO and Co-founder, will present at the Festival of Biologics on March 21, 2023. His talk, titled “Building Biology Overnight”, will focus on overcoming synthesis bottlenecks using hands-free automated synthetic biology solutions, particularly the award-winning BioXp® platform. Dr. Gibson will showcase the new SOLA technology, enhancing DNA synthesis by efficiently assembling complex synthetic genes and mRNA templates through a pre-manufactured library of short DNA oligos. This innovation aims to expedite timelines for applications in vaccine and therapeutics development.
Telesis Bio Inc. (NASDAQ: TBIO) announced its participation at the RNA Leaders Europe Congress in Basel, Switzerland, on March 15, 2023, to showcase its benchtop automation solutions for mRNA synthesis. Presentations will include insights on optimizing CAR-T development workflows and addressing mRNA synthesis bottlenecks. The award-winning BioXp® system allows automated mRNA synthesis from sequence or plasmid DNA, enabling faster acquisition of mRNA in days instead of weeks. Dr. Todd R. Nelson, CEO, asserts that this technology is crucial for accelerating drug discovery, particularly in oncology and vaccine development.
Telesis Bio (Nasdaq: TBIO) announced the release date for its fourth quarter and full year 2022 financial results, set for March 21, 2023, after market close. Management will host a conference call at 1:30 p.m. PT to discuss the results and corporate highlights. The event is accessible via the Investor section of their website. Telesis Bio specializes in automated multi-omic and synthetic biology solutions, providing technologies like Gibson Assembly and the BioXp system, aimed at enhancing synthetic biology workflows for advancements in precision medicine, vaccine development, and genome editing.
FAQ
What is the current stock price of TELESIS BIO (TBIO)?
What is the market cap of TELESIS BIO (TBIO)?
What is Telesis Bio, Inc. known for?
What are the main products offered by Telesis Bio?
How does the BioXp® system benefit researchers?
What recent achievements has Telesis Bio announced?
What is the Gibson SOLA platform?
Where is Telesis Bio located?
How has Telesis Bio performed financially recently?
What industries benefit from Telesis Bio's technology?
How can I learn more about Telesis Bio's offerings?
What are Telesis Bio's future plans?
